Flavopiridol inhibits interferon-γ-induced nitric oxide production in mouse vascular endothelial cells

Immunology Letters

Volumn 148, Issue 2, 2012, Pages 91-96

  Terashima, Tsuguaki ^a   Haque, Abedul ^a   Kajita, Yuka ^a   Takeuchi, Akinori ^a   Nakagawa, Takashi ^a   Yokochi, Takashi ^a  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Flavopiridol (FP); Inducible NO synthase (iNOS); Interferon gamma (IFN ); Nitric oxide (NO); Signal transducer and activator of transcription 1 (STAT1); Vascular endothelial cells

Indexed keywords

FLAVOPIRIDOL; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR 1; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERFERON REGULATORY FACTOR 1; MESSENGER RNA; NITRIC OXIDE; STAT1 PROTEIN;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL SURFACE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENDOTHELIUM CELL; FLOW CYTOMETRY; IMMUNOBLOTTING; IMMUNOMODULATION; INTRACELLULAR SIGNALING; METABOLIC INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN INDUCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIAL CELL;

ANIMALS; CELL LINE; CELL SURVIVAL; CYCLIN-DEPENDENT KINASES; ENDOTHELIAL CELLS; ENZYME ACTIVATION; FLAVONOIDS; IMMUNOMODULATION; INTERFERON REGULATORY FACTOR-1; INTERFERON-GAMMA; MICE; NITRIC OXIDE; PIPERIDINES; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR;

EID: 84869176321     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2012.10.004     Document Type: Article

References (39)

1. Naik R.G., Kattige S.L., Bhat S.V., Alreja B., de Souza N.J., Rupp R.H. An antiinflammatory cum immunomodulatory piperidinylbenzopyranone from dysoxylum binectariferum: isolation, structure and total synthesis. Tetrahedron 1988, 44:2081-2086.
2. Sedlacek H., Czech J., Naik R., Kaur G., Worland P., Losiewicz M., et al. Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy. Int J Oncol 1996, 9:1143-1168.
3. Takada Y., Aggarwal B.B. Flavopiridol inhibits NF-kappaB activation induced by various carcinogens and inflammatory agents through inhibition of IkappaBalpha kinase and p65 phosphorylation: abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9. J Biol Chem 2004, 279:4750-4759.
4. Kelland L.R. Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status. Expert Opin Investig Drugs 2000, 9:2903-2911.
5. Zhai S., Senderowicz A.M., Sausville E.A., Figg W.D. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development. Ann Pharmacother 2002, 36:905-911.
6. Chen R., Gandhi V., Plunkett W. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res 2006, 66:10959-10966.
7. Wang L.M., Ren D.M. Flavopiridol, the first cyclin-dependent kinase inhibitor: recent advances in combination chemotherapy. Mini Rev Med Chem 2010, 10:1058-1070.
8. Schnaiter A., Stilgenbauer S. Refractory chronic lymphocytic leukemia-new therapeutic strategies. Oncotarget 2010, 1:472-482.
9. Jain S.K., Bharate S.B., Vishwakarma R.A. Cyclin-dependent kinase inhibition by flavoalkaloids. Mini Rev Med Chem 2012, 12:632-649.
10. Haque A., Koide N., Iftakhar-E-Khuda I., Noman A.S., Odkhuu E., Badamtseren B., et al. Flavopiridol inhibits lipopolysaccharide-induced TNF-α production through inactivation of nuclear factor-κB and mitogen-activated protein kinases in the MyD88-dependent pathway. Microbiol Immunol 2011, 55:160-167.
11. Pautz A., Art J., Hahn S., Nowag S., Voss C., Kleinert H. Regulation of the expression of inducible nitric oxide synthase. Nitric Oxide 2010, 23:75-93.
12. Magazine H.I. Detection of endothelial cell-derived nitric oxide: current trends and future directions. Adv Neuroimmunol 1995, 5:479-490.
13. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J 1992, 6:3051-3064.
14. Beckman J.S., Koppenol W.H. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 1996, 271:C1424-C1437.
15. MacMicking J., Xie Q.W., Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol 1997, 15:323-350.
16. Kröncke K.D., Fehsel K., Kolb-Bachofen V. Inducible nitric oxide synthase in human diseases. Clin Exp Immunol 1998, 113:147-156.
17. Sharma J.N., Al-Omran A., Parvathy S.S. Role of nitric oxide in inflammatory diseases. Inflammopharmacol 2007, 15:252-259.
18. Marrero M.B., Venema V.J., He H., Caldwell R.B., Venema R. Inhibition by the JAK/STAT pathway of IFNgamma- and LPS-stimulated nitric oxide synthase induction in vascular smooth muscle cells. Biochem Biophys Res Commun 1998, 252:508-512.
19. Schroder K., Hertzog P.J., Ravasi T., Hume D.A. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 2004, 75:163-189.
20. Stempelj M., Kedinger M., Augenlicht L., Klampfer L. Essential role of the JAK/STAT1 signaling pathway in the expression of inducible nitric-oxide synthase in intestinal epithelial cells and its regulation by butyrate. J Biol Chem 2007, 282:9797-9804.
21. Green S.J., Scheller L.F., Marletta M.A., Seguin M.C., Klotz F.W., Slayter M., et al. Nitric oxide: cytokine-regulation of nitric oxide in host resistance to intracellular pathogens. Immunol Lett 1994, 43:87-94.
22. Liew F.Y. Nitric oxide in infectious and autoimmune diseases. Ciba Found Symp 1995, 195:234-239.
23. Bogdan C., Röllinghoff M., Diefenbach A. The role of nitric oxide in innate immunity. Immunol Rev 2000, 173:17-26.
24. Morikawa A., Koide N., Kato Y., Sugiyama T., Chakravortty D., Yoshida T., et al. Augmentation of nitric oxide production by gamma interferon in a mouse vascular endothelial cell line and its modulation by tumor necrosis factor alpha and lipopolysaccharide. Infect Immun 2000, 68:6209-6214.
25. Green L.C., Wagner D.A., Glogowski J., Skipper P.L., Wishnok J.S., Tannenbaum S.R. Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Anal Biochem 1982, 126:131-138.
26. Hassan F., Islam S., Tumurkhuu G., Naiki Y., Koide N., Mori I., et al. Intracellular expression of toll-like receptor-4 in neuroblastoma cells and their unresponsiveness to lipopolysaccharide. BMC Cancer 2006, 8:281-288.
27. Farrar M.A., Campbell J.D., Schreiber R.D. Identification of a functionally important sequence in the C terminus of the interferon-gamma receptor. Proc Natl Acad Sci USA 1992, 89:11706-11710.
28. Kamijo R., Harada H., Matsuyama T., Bosland M., Gerecitano J., Shapiro D., et al. Requirement for transcription factor IRF-1 in NO synthase induction in macrophages. Science 1994, 263:1612-1615.
29. Vilcek J., Oliveira I.C. Recent progress in the elucidation of interferon-gamma actions: molecular biology and biological functions. Int Arch Allergy Immunol 1994, 104:311-316.
30. Müller M., Briscoe J., Laxton C., Guschin D., Ziemiecki A., Silvennoinen O., et al. The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and -gamma signal transduction. Nature 1993, 366:129-135.
31. Silva C.M., Lu H., Weber M.J., Thorner M.O. Differential tyrosine phosphorylation of JAK1, JAK2, and STAT1 by growth hormone and interferon-gamma in IM-9 cells. J Biol Chem 1994, 269:27532-27539.
32. Pestka S. The interferon receptors. Semin Oncol 1997, 24:18-40.
33. Lee Y.K., Isham C.R., Kaufman S.H., Bible K.C. Flavopiridol disrupts STAT3/DNA interactions, attenuates STAT3-directed transcription, and combines with the Jak kinase inhibitor AG490 to achieve cytotoxic synergy. Mol Cancer Ther 2006, 5:138-148.
34. Deng J., Grande F., Neamati N. Small molecule inhibitors of Stat3 signaling pathway. Curr Cancer Drug Targets 2007, 7:91-107.
35. Billard C., Kern C., Tang R., Ajchenbaum-Cymbalista F., Kolb J.P. Flavopiridol downregulates the expression of both the inducible NO synthase and p27(kip1) in malignant cells from B-cell chronic lymphocytic leukemia. Leukemia 2003, 17:2435-2443.
36. Billard C., Quiney C., Tang R., Kern C., Ajchenbaum-Cymbalista F., Dauzonne D., et al. The inducible NO synthase is downregulated during apoptosis of malignant cells from B-cell chronic lymphocytic leukemia induced by flavopiridol and polyphenols. Ann N Y Acad Sci 2003, 1010:381-383.
37. Dai Y., Grant S. Small molecule inhibitors targeting cyclin-dependent kinases as anticancer agents. Curr Oncol Rep 2004, 6:123-130.
38. Shapiro G.I. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006, 24:1770-1783.
39. Krystof V., Uldrijan S. Cyclin-dependent kinase inhibitors as anticancer drugs. Curr Drug Targets 2010, 11:291-302.